Cilengitide is an integrin inhibitor with antiangiogenic activity and was used in clinical trials combined with standard treatment, both for MGMT promoter-methylated and unmethylated glioblastomas.5,6 No survival benefit was found with the addition of cilengitide in either group. The gene discussed is MGMT; the disease is glioblastoma.